Table 3.

MASES, tender joint count, and swollen joint count by sex, HLA-B27 positivity, and concomitant DMARD use

	All	Male	Female	HLA-B27-negative	HLA-B27-positive	No concomitant DMARD at baseline	Concomitant DMARD at baseline
	Median First quartile, third quartile [95% confidence interval]
Patients with enthesitis, MASES ≥ 1 at baseline
MASES: 0 to 13, number (percentage)	667 (100)	431 (64.6)	236 (35.4)	126 (18.9)a	523 (78.4)a	499 (74.8)	168 (25.2)
Baseline	5 2, 8	4 2, 7	7 4, 9	5 2, 9	5 2, 8	5 2, 8	4 2, 8
Week 12	1 0, 4	0 0, 2	1 0, 5	1 0, 5	0 0, 3	0 0, 3	1 0, 4
Change from baseline to week 12	-2 -5,-1 [-3 to -2]	-2 -5,-1 [-3 to -2]	-3 -6,-1 [-4 to -2]	-2 -5,-1 [-3 to -2]	-3 -6,-1 [-3 to -2]	-3 -5,-1 [-3 to -2]	-2 -5,-1 [-5 to -2]
Patients with peripheral arthritis, SJC ≥ 1 at baseline
TJC: 0 to 46, number (percentage)	281 (100)	175 (62.2)	106 (37.7)	57 (20.3)a	217 (77.2)a	170 (60.5)	111 (39.5)
Baseline	5 2, 12	4 2, 10	7 3, 14	6 3, 13	5 2, 12	4 2, 10	6 3, 13
Week 12	1 0, 3	1 0, 3	1 0, 4	1 0, 4	0 0, 3	0 0, 3	1 0, 4
Change from baseline to week 12	-3 -8,-1 [-4 to -2]	-2 -6,-1 [-3 to -2]	-4 -10,-2 [-6 to -3]	-3 -10,-1 [-6 to -2]	-3 -7,-1 [-4 to -2]	-2 -7,-1 [-3 to -2]	-3 -9,-2 [-4 to -2]
SJC: 0 to 44, number (percentage)	281 (100)	175 (62.2)	106 (37.7)	57 (20.3)a	217 (77.2)a	170 (60.5)	111 (39.5)
Baseline	2 1, 4	2 1, 3	2 1, 6	2 1, 6	2 1, 4	2 1, 3	2 1, 6
Week 12	0 0, 1	0 0, 1	0 0, 1	0 0, 1	0 0, 1	0 0, 1	0 0, 1
Change from baseline to week 12	-1 -3,-1 [-2 to -1]	-1 -3,-1 [-2 to -1]	-2 -4,-1 [-2 to -1]	-1 -4,-1 [-2 to -1]	-1 -3,-1 [-2 to -1]	-1 -2,-1 [-1 to -1]	-2 -4,-1 [-2 to -2]

^aBecause of missing data, the percentages of patients with HLA-B27 status do not sum to 100%. DMARD, disease-modifying antirheumatic drug; MASES, Maastricht Ankylosing Spondylitis Enthesitis Score; SJC, swollen joint count; TJC, tender joint count.